These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12172343)

  • 1. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.
    Spina E; Avenoso A; Scordo MG; Ancione M; Madia A; Gatti G; Perucca E
    J Clin Psychopharmacol; 2002 Aug; 22(4):419-23. PubMed ID: 12172343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma risperidone concentrations during combined treatment with sertraline.
    Spina E; D'Arrigo C; Migliardi G; Morgante L; Zoccali R; Ancione M; Madia A
    Ther Drug Monit; 2004 Aug; 26(4):386-90. PubMed ID: 15257068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.
    Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia A
    Ther Drug Monit; 2001 Jun; 23(3):223-7. PubMed ID: 11360029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia.
    D'Arrigo C; Migliardi G; Santoro V; Morgante L; Muscatello MR; Ancione M; Spina E
    Pharmacol Res; 2005 Dec; 52(6):497-501. PubMed ID: 16226034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
    Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
    J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone plasma levels, clinical response and side-effects.
    Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; De Vries R; Kaneko S
    J Clin Pharmacol; 2002 Oct; 42(10):1083-8. PubMed ID: 12362921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis.
    Paulzen M; Haen E; Stegmann B; Hiemke C; Gründer G; Lammertz SE; Schoretsanitis G
    Psychoneuroendocrinology; 2016 Nov; 73():9-15. PubMed ID: 27448523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
    Kneller LA; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
    Paulzen M; Haen E; Hiemke C; Stegmann B; Lammertz SE; Gründer G; Schoretsanitis G
    Br J Clin Pharmacol; 2017 Aug; 83(8):1668-1675. PubMed ID: 28160505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.
    Aman MG; Vinks AA; Remmerie B; Mannaert E; Ramadan Y; Masty J; Lindsay RL; Malone K
    Clin Ther; 2007 Jul; 29(7):1476-86. PubMed ID: 17825699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
    Spina E; Avenoso A; Facciolà G; Salemi M; Scordo MG; Ancione M; Madia AG; Perucca E
    Psychopharmacology (Berl); 2001 Jan; 153(2):238-43. PubMed ID: 11205425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.
    Berecz R; LLerena A; de la Rubia A; Gómez J; Kellermann M; Dorado P; Degrell I
    Pharmacopsychiatry; 2002 Nov; 35(6):231-4. PubMed ID: 12518271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
    Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
    Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.
    Roh HK; Kim CE; Chung WG; Park CS; Svensson JO; Bertilsson L
    Eur J Clin Pharmacol; 2001 Nov; 57(9):671-5. PubMed ID: 11791898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.
    Suzuki Y; Fukui N; Tsuneyama N; Watanabe J; Ono S; Sugai T; Saito M; Inoue Y; Someya T
    Hum Psychopharmacol; 2012 Jan; 27(1):43-6. PubMed ID: 22745940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
    Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
    Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
    Andrade C
    J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.